Oragenics Advances Phase IIa Trial for Concussion Treatment, Eyes CNS Expansion

Oragenics Inc. (NYSE American: OGEN) provided a shareholder update on Monday, detailing progress in its Phase IIa clinical trial of ONP-002 for concussion and mild traumatic brain injury (mTBI) and outlining strategic expansion plans in the central nervous system (CNS) space. The company reported active patient enrollment and dosing across multiple sites in Australia, with preparations underway for U.S. regulatory steps, including a planned Type C meeting request with the FDA in the second quarter and an Investigational New Drug (IND) submission targeted by year-end 2026.

The update highlights Oragenics’ commitment to addressing the significant unmet medical need in concussion and mTBI, conditions that affect millions worldwide each year. ONP-002, delivered via the company’s proprietary intranasal delivery technology, aims to provide rapid, non-invasive treatment directly to the brain, potentially offering a first-in-class option for a market currently lacking approved pharmacotherapies.

In addition to clinical progress, Oragenics disclosed a letter of intent to pursue licensing of a complementary CNS-related medical device, signaling a strategic expansion beyond its lead drug candidate. The company reported a cash balance of $6.1 million as of March 31, 2026, which is expected to fund operations through key milestones, including the U.S. regulatory interactions.

The intranasal delivery platform underpinning ONP-002 has potential applications across multiple neurological conditions, including Parkinson’s disease, Alzheimer’s disease, PTSD, and anxiety disorders, according to the company. This broad applicability underscores the platform’s versatility and positions Oragenics for potential pipeline expansion.

For investors seeking detailed information, the full press release is available at https://ibn.fm/tEk2C, and the latest news and updates on OGEN can be found in the company’s newsroom at https://ibn.fm/OGEN.

The advancement of ONP-002 through clinical trials and the exploration of adjacent CNS opportunities highlight Oragenics’ strategic focus on neurological care. With the Phase IIa trial progressing in Australia and U.S. regulatory pathways being prepared, the company is positioning itself to address a critical gap in the treatment of concussion and mTBI, while also leveraging its technology for other neurological disorders.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Oragenics Advances Phase IIa Trial for Concussion Treatment, Eyes CNS Expansion.

The post Oragenics Advances Phase IIa Trial for Concussion Treatment, Eyes CNS Expansion appeared first on citybuzz.